Pearce IP BioBlast™: w/e 20 March 2020

by , | Mar 23, 2020

Significant biosimilar activities this week include

16 Mar 20 | Teva and Celltrion launched Herzuma (trastuzumab) in the US. Herzuma is indicated for the treatment of breast cancer, metastatic breast cancer and metastatic gastric cancer.

19 Mar 20 | The Centre for Biosimilars reported on a pair of biosimilar bills which were introduced to the US Congress in the 2 weeks prior. These bills include a ‘shared savings’ model designed to encourage physicians to switch patients to biosimilars, and a program that would allow $0 co-pays for seniors prescribed biosimilars.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to recieve our updates via email.

Our Latest News